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ABSTRACT  
THE ROLES OF CERAMIDE METABOLIZING GENES ON 
RESVERATROL INDUCED APOPTOSIS IN HUMAN HL60 ACUTE 
MYELOID LEUKEMIA CELLS 
 
Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is naturally occurring phytoalexin, 
which presents especially in grapes. It is a potential anticancer agent which inhibits 
tumor initiation, promotion, and progression. Ceramides are the central compounds of 
sphingolipids metabolism. They are known as second messengers regulating various 
cellular processes including cell growth, proliferation, differentiation and apoptosis. 
While ceramide acts as a strong apoptotic molecule, glucosylceramide (GluCer) and 
sphingosine-1-phosphate (S1P) trigger cell growth and proliferation and inhibit 
apoptosis. Sphingosine kinase-1 (SK-1) is an enzyme catalyzing the phosphorylation of 
sphingosine to sphingosine-1-phosphate while glucosylceramide synthase (GCS) 
converts ceramide to glucosylceramide. Thus, inhibition of GCS by N-(2-hydroxy-1-(4-
morpholinylmethyl)-2-phenylethyl)-decanamide, hydrochloride (PDMP) or SK-1 by 
sphingosine kinase-1 inhibitor, or exogenous application of ceramide analog 
(C8:ceramide) results in increased accumulation of ceramides. The aim of the study is  
to examine the roles of ceramide, glucosylceramide and sphingosine-1-phosphate in 
resveratrol induced apoptosis in HL60 cells. 
In this study, it was demonstrated cytotoxic effects of resveratrol on human 
acute myeloid leukemia cells in addition to identify a novel mechanism of resveratrol-
induced apoptosis by targeting ceramide metabolism. And also it was shown that via 
targeting ceramide-generating and/or ceramide-clearance genes provided ceramide 
generation and/or accumulation in response to resveratrol treatment. This study showed 
for the first time that there were significant induction of apoptosis through increasing 
intracellular concentrations of ceramides in resveratrol treated HL60 cell. Taking 
together all these results showed that ceramides may be involved in resveratrol-induced 
apoptosis. 
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ÖZET 
ĠNSAN HL60 AKUT MĠYELOĠD LÖSEMĠ HÜCRELERĠNDE 
RESVERATROLÜN TETĠKLEDĠĞĠ PROGRAMLI HÜCRE ÖLÜMLERĠ 
ÜZERĠNE SERAMĠD METABOLĠZMASI GENLERĠNĠN ROLLERĠ 
Resveratrol, doğal olarak bitkilerde oluşan anti-oksidan bir fitoaleksindir.  En 
çok  kırmızı üzüm ve diğer bazı meyvelerde bulunur. Resveratrolün hücre içindeki 
fonksiyonları anti-oksidan ve anti-inflamatuar, tümör oluşumunu ve ilerlemesini inhibe 
etmesidir. Seramidler; hücrede büyüme, farklılaşma ve apoptoz gibi çok önemli 
metabolik proseste görev alan hücrenin membranlarında bulunan yapısal bir 
moleküldür. Seramid metabolizmasında rol alan kritik enzimler, sfingozin kinaz-1 ve 
glukozilseramid sentazdır. Seramidler apoptotik sfingozine seramidazlar ile dönüşür ve 
bu sfingozinler; sfingozin kinaz-1’ler ile sfingozin-1-fosfata fosfatlanırlar. Sfingozin-1-
fosfat, hücrenin yaşamını ve proliferasyonunu sağlar ve  apoptozu inhibe eder. 
Sfingozin kinaz-1 enziminin inhibe edilmesi sonucu seramid birikimi 
sağlanabilmektedir. Glukozilseramid sentaz (GSS) enzimi, seramidin glukozilseramide 
glukozillenmesini katalizler. Glukozilseramid ise kanser hücrelerinde ilaç dirençliliğine 
yol açan bir moleküldür. GSS’nin, PDMP ile inhibisyonu ilaç dirençliliğine neden olan 
genlerin ekspresyon düzeyinin düşmesine ve aynı zamanda seramid birikmini 
sağlayarak kanser hücrelerinin apoptoza gitmelerine neden olmaktadır.  
Resveratrolün tek başına ya da resveratrol ile kombine edilen seramidlerin, SK-1 
inhibitörü ve PDMP’nin HL60 hücreleri üzerine sitotoksik ve apoptotik etkileri 
gösterilmiştir. Ve ayrıca  seramid metabolize eden genlerin expresyon düzeylerindeki 
değişimler RT-PCR ile gösterilerek CerS 1, 2, 4, 5, 6 genlerinin düzeyindeki artışlar ile 
SK-1 ve GSS genlerinin düzeylerindeki azalışlar gösterilmiştir. Resveratrol uygulanan 
HL60 hücrelerinde, seramid biyosentezinde görev alan enzimlerin gen düzeylerindeki 
artışlar ile seramidi metabolize eden genlerin düzeylerindeki azalışlar sonucu seramidin 
birikimi sağlanarak hücrelerin apoptoza girmeleri kanser tedavisinde yeni bir tedavi 
yöntemi olarak düşünülebilir. 
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CHAPTER 1                                                               
INTRODUCTION 
1.1. Acute Myeloid Leukemia (AML) 
 
Acute Myeloid Leukemia is characterized with the rapidly growing of immature 
blood cells and could be fatal within few weeks if it is untreated (Shipley and Butera, 
2009). In AML disease, neoplastic cells are accumulated in the bone marrow, as a 
consequence hematopoiesis is blocked, in other words leukemic cells replace with 
normal bone marrow cells. This causes decreases in number of normal platalets, red 
blood cells and white blood cells. This type of leukemia is resulted from variety type of 
translocation or inversion at the chromosomal break (Shipley and Butera, 2009). After 
formation of these variety abnormalities in the chromosome, they encode for proteins 
with the aberrant functions. These aberrant proteins are also called as ‘fusion proteins’. 
Generally, fusion proteins are made up of a transcription factor and a protein which is 
related with cell survival and apoptosis in its structure (Alcalay, et al., 2001). 
Transcription factor, which is found in fusion protein, have effect on myeloid 
differentiation and hematopoiesis in certain types of AML. The common gene 
rearrangements are t(15;17) PML-RARα; t(8;21) AML1-ETO; 11q23 MLL 
rearrangements, and Inv(16), CBFβ-MYH11 in AML (Martens and Stunnenberg, 2010). 
It is clear that the evaluation of AML pathogenesis is very crucial issue in order to 
treatment of AML, therefore AML have distinct sutbtypes in terms of cytogenetics. 
Therefore, there are two classification is commonly used for classifying AML. One of 
them is World Health Organization (WHO) and the other one is The French-American-
British (FAB) Classification. WHO classification is more prevalent as compared to 
FAB classification. 
 
1.1.1. The Classification of Acute Myeloid Leukemia 
 
WHO organization classified AML into subtypes according to chromosomal 
translocations in 2008. The  classification of AML contain biological features 
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(morphology, cytogenetics, immunophenotype) and clinical datas. Table I shows the 
classification of AML according to 2008 WHO organization.  
 
Table  1.1. WHO Classification of AML 
 AML with recurrent genetic abnormalities 
o AML with t(8;21)(q22;q22); (RUNX1-RUNX1T1) 
o AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); (CBFB-
MYH11) 
o Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); (PML-
RARA) 
o AML with t(9;11)(p22;q23); (MLLT3-MLL) 
o AML with t(6;9)(p23;q34); (DEK-NUP214) 
o AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); (RPN1-EVI1) 
o AML (megakaryoblastic) with t(1;22)(p13;q13); (RBM15-MKL1) 
o Provisional entity: AML with mutated NPM1 
o Provisional entity: AML with mutated CEBPA 
 AML with MDS-related changes 
 Therapy-related myeloid neoplasms 
 AML-NOS 
o AML with minimal differentiation 
o AML without maturation 
o AML with maturation 
o Acute myelomonocytic leukemia 
o Acute monoblastic/monocytic leukemia 
 Acute erythroid leukemias 
 Pure erythroid leukemia 
 Erythroleukemia, erythroid/myeloid 
 Acute megakaryoblastic leukemia 
 Acute basophilic leukemia 
 Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
 Myeloid proliferations related to Down syndrome 
o Transient abnormal myelopoiesis 
o AML associated with Down syndrome 
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1.1.2. Acute Promyelocytic Leukemia (APL) 
 
Acute Promyelocytic Leukemia (APL) is a subtype of M3-Acute Myeloid 
Leukemia according to the FAB classification which constitutes of ~10% of AML cases 
(Tallman, 2008). The frequency of this disease is rare, however it is distinct from the 
other AMLs with its molecular biology and clinical outcomes. The main clinical 
outcome of APL disease is the  accumulation of progenitor myeloids, promyelocytes, in 
bone marrow that is based on frustrated differentiation of promyelocytes (Pandolfi, et 
al., 2001). 
APL is characterized with the reciprocal translocation between chromosome 17 
and variety of partner chromosomes such as 11, 5, 11, 17 (PLZF, NPM, NuMA, 
STAT5b, respectively) and generally translocation is observed between chromosomes 
17 and 15 (Piazza, et al., 2001). Retinoic Acid Receptor α (RARα) gene located on 
chromosome 17 and it is involved in all APL cases, fuses generally with PML which are 
located on choromosome 15. The cells which carry PML/RARα translocation are 
genetically unstable (Wang, et al., 1998). 
   Production of PML/RARα fusion protein shows oncogenic activity and blocks 
myeloid differentiation.  Several studies showed that PML/RARα translocation caused 
accelerated level of leukemogenesis both in vivo and in vitro (Pandolfi, et al., 2001) 
(Figure 1.1). 
PML/RARα have oncogenic activity at only few type of cells. In fibroblasts, this 
translocation has no effect on growth however, in non-hematopoietic cells, PML/RARα 
has growth inhibitory effects, predominantly in hematopoietic cells (Ferrucci, et al., 
1997). It is still unclear why PML/RARα translocation cause oncogenic transformation 
only in specific type of cells. Hematopoietic progenitors which contain PML/RARα 
fusion protein is resistant to apoptotic stimuli, but still the role of PML/RARα on cell 
cycle regulation is not clear.  
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Figure  1.1. PML/ RAR α Fusion Protein Leads to Oncogenic Activation in      
Hematopoietic Cells (Source: Adapted from Pandolfi, 2001) 
 
The apoptotic stimulis Fas, TNF and interferons are unresponsive in APL cells 
(Wang, et al., 1998). PML interacts with p53 both in vivo and in vitro. PML is required 
for acetylation of p53 in response to γ-irradiation and activates p53 downstream targets 
such as Bax. PML is not only contributed to p53-dependent pathway, but also 
contributed to p53-independent pathway (Zhong, et al., 2000) (Figure 1.2).  
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Figure  1.2. Consequence of PML/ RAR α translocation in PML function 
(Source:Adapted from Pandolfi,2001) 
 
1.2. Treatment Strategies for Acute Promyelocytic Leukemia 
 
AML comprises %32,6 among all leukemia types according to 2007 statistics 
(Jemal, et al., 2007).  The median age of AML is 70 years old. Generally, younger AML 
patients give a respond to therapy however, it is difficult to achieve a respond in older 
AML patients. The standard therapy in AML is administration of  cytarabine and 
anthracyclines such as daunorubicin or idarubicin for the patients of all ages. On the 
other hand in APL patients, the standard therapy is both administration of all-trans 
retinoic acid (ATRA) and anthracycline-based chemotherapy. Another treatment 
approach is administration of Arsenic Trioxide (ATO) (Sanz, 2006). Molecular 
mechanism of ATRA is induction of differentiation of progenitor neoplastic cells into 
mature granulocytes. After this irreversible differentiation, leukemic cells enter to 
apoptotic cell death (Gianni, et al., 2000). ATO is generally used in ATRA resistant 
patients. ATO reacts with incomplete differentiated cells and induce apoptosis via 
activation of caspases in leukemic cells  (Shen, et al., 1997). It was reported that 
hematopoietic stem cell transplantation (HSCT) is not suggested in the first line therapy 
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in APL patients. After ATO or gemtuzumab, HSCT approach can be considered to 
apply for patients (Tallman, 2007).  
Antibodies are also used in APL patients. Gemtuzumab-ozogamicin is one of 
this conjugated antibodies which determines and binds to CD33 cell surface marker. 
Gemtuzumab-Ozogamicin is internalized into leukemic cell and conjugated 
calicheamicin is released and leads to DNA damage and cell death. Calicheamicin 
belongs to antracycline group which is also effective chemotherapeutic agent in APL 
treatment  (Lo-Coco, et al., 2003). 
 
1.3. Resveratrol  
 
Resveratrol (trans-3,5,4’-trihydroxystilbene, C14H12O3) is a polyphenol that  
have beneficial effects on body.  
 
 
Figure  1.3. The Representation of Resveratrol Structure 
(Source: Kraft et al., 2009) 
 
Resveratrol, as a phytoalexin, is derived from plants such as red grape seed and 
skin, blueberry, peanuts and red wine. It was firstly isolated from the roots of white 
hellebore and then from Polygonum cupsidatum (Baur and Sinclair, 2006). Phytoalexin 
is a toxic molecule for foreign attacts. Resveratrol is synthesized in plants in response to 
stress, bacterial or fungal attacks and UV-irradiation. Mostly, it is synthesized in the 
form of trans- configuration because it is thermordynamically stable. 
It is known that red wine contains high concentration of resveratrol. 
Consumption of red wine is correlated with the low risk of cardiovascular diseases in 
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French population as compared to other industrial countries. This phenomenon is 
known as French paradox (Richard, 1987).   
 
 
Figure  1.4. The Sources of Resveratrol 
(Source: Adapted from Shakibaei et al.,2009) 
 
 
1.3.1. Biosynthesis of Resveratrol in Plants 
 
Resveratrol is synthesized via phenylpropanoid pathway in plants (Figure 1.5). 
Phenylalanine is converted to cinnamic acid by phenylalanine ammonia lyase (PAL) 
and cinnamic acid is transformed into p-coumaric acid (4-coumaric acid) by cinnamic 
acid 4-hydroxylase (C4H). Then, the enzyme 4-coumarate:CoA ligase (4CL) adds p-
coumaric acid to pantetheine group of Coenzyme-A (CoA) and generates 4-coumaroyl-
CoA. After that condensation of  p-coumaroyl-CoA and malonyl-CoA form resveratrol. 
Malonyl-CoA is generated from fatty acid biosynthesis (Halls and Yu, 2008). 
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Figure  1.5. Biosynthetic Pathway of Resveratrol  
(Source: Halls et al., 2008) 
 
1.3.2. The Roles of Resveratrol in Mammalian Cells and Possible   
Medical Application 
 
Plant-derived resveratrol targets many intracellular molecules in mammalian 
cells and activates signaling molecules and enzymes in the cell. The best known target 
of resveratrol is Sirtuin (SIRT) 1 to 7 enzymes which is involved in DNA repair, cell 
survival, gluconeogenesis, muscle cell differentiation, cell cycle regulation, lipid 
metabolism, fat mobilization and insulin sensitivity  (Brooks and Gu, 2009). The 
activation of SIRTs by mediating of resveratrol augments against aging (Brooks and 
Gu, 2009).  
Resveratrol binds to various cell-signaling molecules and modulates cell-cycle 
regulatory genes. It activates transcription factors, inhibits protein kinases and the 
expression of antiapoptotic genes, as well as angiogenic and metastatic gene products 
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and inflammatory biomarkers, induces antioxidant enzymes, and alters the expression of 
enzymes such as cytochrome P450s that are involved in drug metabolism (Baur and 
Sinclair, 2006). Resveratrol increases the activity of endothelial nitric oxide synthase 
enzyme which synthesize vasodilator molecule nitric oxide (Nicholson, et al., 2008). On 
the other hand resveratrol inhibits platelet aggregation and protects body from 
cardiovascular diseases (Das and Das, 2010). 
Resveratrol is widely known due to its antioxidant activity. With this property, 
resveratrol scavenges superoxide and peroxynitrite radicals by forming enzymatically or 
non-enzymatically(de la Lastra and Villegas, 2007). Reactive oxygen species (ROS) are 
mostly generated as byproducts in metabolism. These molecules are highly reactive and 
may give damage to DNA. Resveratrol protects towards DNA damage caused by  ROS 
(Jagdeo, et al., 2010). 
One of the such roles of resveratrol are inducing apoptosis and inhibiting anti-
apoptotic molecules. It was found that resveratrol activates death receptor such as 
CD95/Fas system in HL60, T47D breast carcinoma cells and colon carcinoma cells 
(Clement, et al., 1998 and Delmas, et al., 2003). Also, resveratrol may induce apoptosis 
intrinsically beside that induction of apoptosis via extrinsically. Resveratrol inhibits 
FIF0 ATP synthase and increases apoptotic molecules such as Bax and p53 is also 
involved in resveratrol-induced apoptosis and upregulates expression of p21
cip1
 and 
GADD45 which are downstream targets of p53 (Lu, et al., 2001). Resveratrol interacts 
with tyrosine kinases which are generally upragulated in many types of cancer and 
inhibits Src kinases and MAPK pathway (Shen, et al., 2003). Activator protein-1 (AP-1) 
is normally elevated in cancer and upregulates Fos and Jun families and effects 
transcription factors. However, it was found that resveratrol suppressed AP-1 
stimulation (Manna, et al., 2000).  
Szende et al. demonstrated that resveratrol inhibited VEGF activation and 
prevented angiogenesis in HUVEC (human umbilical vein endothelial cells) cells 
(Szende, et al., 2000). And also resveratrol induced proteolytic degradation of MMPs 
which are involved in angiogenesis (Cucciolla, et al., 2007). 
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1.3.3. Chemotherapeutic Effects of  Resveratrol in Cancer Models 
 
Resveratrol has broad spectrum effects from anti-oxidant properties to anti-
inflammatory effects on mammary cells. After finding of these properties, Jang et al. 
demonstrated for the first time resveratrol has anti-carcinogenic effects on cancer cells 
in 1997 (Jang et al,1997). Then, researchers tend to find molecular mechanisms of 
resveratrol on cancer cells. And it was reported that resveratrol inhibits initiation, 
promotion and progression of carcinogenesis, also sensitized chemoresistant or 
radioresistant cells to apoptosis and metastasis (Garg, et al., 2005). One of the most 
important point in chemotherapy is regulation of cell proliferation and survival. Some of 
the chemotherapeutic agents target cell cycle regulatory proteins such as cyclin-
dependent kinase (cdk) inhibitors and check point kinases (chk). Resveratrol suppressed 
cyclin D1, D2 and E and reduced the level of Retinoblastoma protein in A431 
epidermoid carcinoma cells (Kim, et al., 2006). Therefore, resveratrol may be 
considered as a good chemotherapeutic agent. 
Resveratrol has antiproliferative roles in many types of cancer such as breast, 
prostate, lung cancers, melanoma, colorectal and gastric cancer and leukemias (Athar, et 
al., 2007). In prostate cancer cells, resveratrol downregulated androgen-responsive 
genes, including prostate-specific antigen (PSA), human glandular kallikrein-2, AR 
(androgen receptor)-specific coactivator ARA70 (Mitchell, 1999) and also activated 
apoptotic molecules in LnCap prostate cancer cells (Aziz, 2006)  and MAPK signaling 
and finally activation of p53 in LnCap cells (Lin, et al., 2002). 
The molecular structure of resveratrol is similar to synthetic estrogen and can be 
considered as a phytoestrogen. In breast cancer, resveratrol binds to both α and β 
estrogen receptors and (17-beta-estradiol) E2 and inhibits the growth of MCF-7 and  
(Lu and Serrero, 1999), highly invasive MDA-MB-435 cells (Hsieh, et al., 1999). 
The environmental pollutants and cigarette smokes contain very harmful 
carcinogens. Benzo[a]pyrene  and PAH (polycyclic aromatic hydrocarbons) are one of 
these metabolites in human and have crucial roles in lung cancer (Sabapathy, et al., 
2004). Resveratrol changed the expression levels of PAH and BaP metabolizing 
enzymes such as cytocrome P450 (1A1 (CYP1A1) and 1B1 (CYP1B), and glutathione 
S-transferase P1 (GSTP1) genes (Mollerup, et al., 2001). 
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Resveratrol induced apoptosis via activation of CD95/CD95 system in HL60 
and U937 leukemic cell lines. (Clement, et al., 1998). However, in ALL cells which are 
resistant to CD95 signaling, induced apoptosis via CD95 signaling independent pathway 
and activating cell death via mitochondria depolarization and activation of caspase-9  in 
resveratrol treated cells (Dorrie, et al., 2001). 
 
1.4. Bioactive Sphingolipids 
 
Sphingolipids are a components of membrane lipids which are found in lipid 
rafts and contribute to many functional roles beside structural roles in the cell. 
Sphingolipids have roles in differentiation, survival, apoptosis and proliferation. The 
member of sphingolipid families are ceramide, spingosine, sphingosine-1-phosphate, 
glucosylceramide and sphingomyelin (Figure 1.6) (Hannun and Obeid, 2008). 
 
 
Figure  1.6. Ceramide Metabolism and Interconnection Between Ceramide Metabolites 
(Source: Adapted from Hannun, 2008) 
 
It was revealed that in last decades sphingolipids have important roles in cancer 
biology  (Ogretmen, 2006). GluCer and S1P play key roles in cell proliferation and drug 
resistance which means unresponsive to chemotherapeutic agents. On the contrary, 
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ceramide and shingosine have function in apoptosis, differentiation and growth arrest 
(Figure 1.7)  (Ogretmen and Hannun, 2004). 
 
Figure  1.7. Overview of The Roles of Sphingolipids in Cancer Biology 
(Source: Adapted from Hannun, 2008) 
 
1.4.1. Ceramides 
 
1.4.1.1. Structure and Metabolism of Ceramides 
 
Ceramides are made up from sphingosine and amide linked to a variety number 
of fatty acyl chain length (Figure 1.8).  These length of fatty acyl chain varied from C14 
to C26.  
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Figure  1.8. The Molecular Structure of Ceramide 
(Source: Adapted from Ponnusamy, 2010) 
 
Ceramide acts as a precursor molecule and can be converted into other types of 
sphingolipids such as sphingomyelin, sphingosine, glucosylceramide and sphingosine-
1-phosphate in sphingolipids metabolism (Hannun, 1996). Ceramides are generated 
through salvage pathway, sphingomyelinase pathway, recycling of exogenous pathway 
and de novo synthesis. In sphingomyelinase pathway, sphingomyelins are hydrolyzed 
via acid sphingomyelinases or  neutral sphingomyelinases at internal membranes or 
lipid rafts. Neutral sphingomyelinases can be activated via ROS generation in 
mitochondria and generated ceramides (Kitatani, et al., 2008). The term ‘salvage 
pathway’ is recycling of sphingolipids in the late endosomes and lysosomes. Recently, 
it has been found that salvage pathway modulated ceramide formation and metabolism 
(Jin, et al., 2008). In lysosomes, sphingomyelins are degraded via acid 
sphingomyelinases into ceramides and further metabolized to sphingosine and exported 
from lysosomes. However, ceramide seems to not export from the lysosomes and 
remains in the lysosomes (Kitatani, et al., 2008). After degradation of the long chain 
Sphingosine Fatty Acid 
Ceramide 
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sphingoid bases in lysosomes, short chain sphingoid bases are exported from lysosomes 
and contribute to sphingolipid metabolism. Furthermore, family of ceramide synthase 
enzymes synthesize ceramides from long chain sphingosine bases in endoplasmic 
reticulum after releasing from lysosomes (Smith and Merrill, 1995). Exogenous 
ceramides also elevate ceramide levels in the cell. Especially, short chain ceramides 
such as C2 and C6 Ceramides are less non-polar and dissolved in water, therefore they 
could pass from cell membrane easily, contribute to generation of endogenous 
ceramides and take place in ceramide signaling (Dobrowsky and Hannun, 1992). 
 
1.4.1.2. Ceramide Synthases and de novo Generation of Ceramides 
 
De novo synthesis of ceramide starts with condensation of  palmitoyl CoA and 
serine in endoplasmic reticulum (ER). This condensation forms 3-ketosphinganine with 
Serine-Palmitoyl Transferase. Then, 3-Ketosphiganine is converted to sphinganine via 
3-ketosphinganine reductase and finally yields dihydroceramides by ceramide 
synthases. Dihydroceramides are transformed to ceramide by inserting double bonds 
into sphingosine backbone. All of these metabolic reactions occur in the ER and the 
newly synthesized ceramide exports to golgi apparatus by ceramide transfer protein 
(CERT). Ceramides are synthesized with different acyl chains by ceramide synthases 
(CerS)1-6 (Figure 1.9). Ceramide synthase family is actually known as Longevity 
Assurance Gene family (LASS). CerS family show a homology with yeast Longevity 
Assurance gene-1 (LAG-1). CerS1 and CerS4 synthesize C18 Ceramide, CerS2 and 
CerS4 synthesize C20, CerS2 and CerS3 synthesize C22, C24 and C26 Ceramide, 
CerS6 synthesize C14 Ceramide and CerS5 and CerS6 synthesize C16 Ceramide (Levy 
and Futerman, 2010). CerS has Hox-like domain in its structure. Hox domain plays 
important roles in development. Different length of ceramides have different roles in the 
cell such as proliferation, apoptosis, survival and differentiation. CerS1 (LASS1) have 
different characteristic feature as compared to other CerS because of lacking of Hox-
like domains. CerS1 is firstly identified gene and have higher homology to yeast LAG1. 
CerS1 predominantly find in brain, muscle and skeleatal muscle (Riebeling, et al., 
2003). CerS1 is especially have roles in head and neck squamous cell carcinomas 
(HNSCC), also it was found that the balance between C16 and C18 ceramides were 
important in HNSCC pathogenesis (Senkal, et al., 2007). CerS2 is also called LASS2 
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family have Hox-like domain and is found higher levels in kidney and liver (Teufel, et 
al., 2009). Laviad et al. showed that CerS2 is regulated by S1P. Mutation in S1P 
receptor-like motif in CerS2 results in preventing the inhibitory effects of S1P on 
CerS2. The balance between S1P and ceramides are very important in terms of CerS2 
activity. Because this balance decides whether the cell survive or not. Furthermore, 
CerS2 may have roles in unfolded protein response during ER stress (Mullen, et al., 
2011). CerS3 is also known as LASS3 synthesizes C24 Ceramide and involved in 
keratinocyte differentiation (Mizutani, et al., 2008). CerS4 is also called as LASS4 and 
generated C18-22 Ceramide. The expression of CerS4 increase in neurological disease 
such as alzheimer’s disease. CerS5 is also known as LASS5 and it is implicated in 
apoptosis by activation of hypoxia. CerS5 have function in cancer and apoptosis. CerS6 
is also called LASS6 and generated C16 Ceramide. CerS5 and CerS6 show highly 
homology between each other. (Levy and Futerman, 2010).  
  
 
Figure  1.9. Generation of Ceramides with Distinct Chain Lengths 
(Source:Adapted from Ogretmen, 2006) 
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1.4.2. Ceramide and Cancer 
 
Endogenous ceramides have regulatory roles in the cell. They act as a tumor 
suppressor lipids and induce cell cycle arrest, apoptosis, senescence and differentiation. 
Ceramide is accumulated in the cell in response to DNA damage, stress, hypoxia and 
induction of apoptotic molecules (Hannun, 1996). Induction of ceramides activate 
downstream target molecules such as Cathepsin D, RAF, MEKK, Ceramide activated 
protein phosphatases (CAPPs) (Figure 1.10) (Ogretmen and Hannun, 2004). 
Ceramides are known that reside in lipid rafts and interact with Phospholipase 
A2, ceramide-activated protein serine-threonine phosphatases, protein kinase C, c-RAF-
1 and kinase suppressor of RAS. In addition to this, ceramides block calcium release by 
inhibition of activated calcium channels and potassium channels. They contribute to 
forming of ceramide microdomains (Carpinteiro, et al., 2008). But, still the roles of 
these ion channels are not clear, but there may be an evidence that involvement in 
apoptosis via activation of Bax, Bid and Bak (Schneider et al., 2004). Beside these, 
apoptosis is induced by interaction of death receptors such as CD95 and ceramide 
translocated onto extracellular plasma membrane (Grassme, et al., 2001). Kim et al. 
demonstrated that ceramide upregulated p27(kip1) protein levels through induction of 
protein phosphatase 2A (PP2A) in PC-3 prostate cancer cells (Kim, et al., 2010). 
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Figure  1.10. Downstream Targets of Ceramide and Activated Pathways. 
(Source: Ogretmen, 2004) 
 
Ceramides have also functions in induction of quiescence and senescence. It was 
demonstrated that ceramide induced CDK inhibitors such as p27(kip1) in HL60 acute 
myeloid leukemia cells (Kim, et al., 2000). Moreover, ceramides also block the activity 
of protein kinase C and phospholipase D activities (Venable, et al., 1995). 
 
1.4.3. Sphingosine-1-Phosphate (S1P) and Sphingosine Kinases (SK) 
 
Sphingosine-1 Phosphates are biologically important and active molecules. They 
promote cell survival, growth and tumorigenesis (Figure 1.11). S1P is synthesized 
enzymatically via conversion of ceramide to sphingosine and to S1P by ceramidases 
and SKs. SKs have two isoforms which are SK-1 and SK-2 (Pyne and Pyne, 2010). SK-
1 induces cell growth whereas SK-2 inhibits cell growth while overexpression or 
downregulation occurs in SK2. SK-2 activated cell death is independent from S1P 
receptors. SK-1 and SK-2 differ in terms of the function and specifity. SK-1 is more 
dominant than SK-2 to form S1P and activation of cell growth and proliferation. SK-1 is 
highly expressed in solid tumors (Cuvillier, 2007). 
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Figure  1.11. The Targets of S1P in Cancer 
(Source: Pyne and Pyne, 2010)  
 
S1P can bind to sphingosine-1 phosphate receptor (S1PR). S1PRs are G-protein 
coupled receptors that are 1 to 5 S1PR. However, SPR2 is distinct from the other with 
inhibition of migration. And this binding activates signaling cascade and induces 
tyrosine kinases. S1PR interacts with Rac and activates ERK and hence proliferation. 
Also, S1PR2 interacts with Rho and inhibits migration. In cancer cells, SK-1 is 
overexpressed however generally no mutation is encountered in SK-1 and inhibitors of 
SK-1 induces apoptosis in cancer cells such as hodgin lymphoma, lung and colon 
cancers (French, et al., 2003 and Bayerl, et al., 2008).S1P contributes to carcinogenesis 
and interacts with cancer promoting molecules such as VEGF, MAPK and PDGF (Pyne 
and Pyne, 2010). 
 
1.4.4. Glucosylceramide and Glucosylceramide Synthase 
 
Glucosylceramide synthase is the enzyme that transfers glucose from UDP-
glucose to ceramide and produces GlcCer at the cytosolic side of the golgi apparatus 
(Jeckel, et al., 1992). GlcCer contain hydrophobic lipid group and hydrophilic sugar 
group. The function of GlcCer are involvement in proliferation, differentiation and 
tumor metastasis. After formation of GlcCer, it is converted further to gangliosides and 
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cerebrosides. GCS is a key enzyme in development of multidrug resistance. The activity 
of GCS is increased in multidrug resistant cells. Multidrug resistant cells are 
unresponsive to chemotherapeutic agents. It was showed that GCS activity especially 
increases in breast cancer, leukemia and melanoma (Senchenkov, et al., 2001 and 
Ogretmen, 2001).  GCS activity is related wtih P-gp which is a ABC transporter protein 
and efflux agents from cytoplasm. This causes development of resistance to 
chemotherapeutics in the cancer cells. 
 
1.4.5. Targeting of Bioactive Sphingolipids in Cancer Therapy  
 
Sphingolipids as a effector molecules regulate many cellular events such as cell 
growth, proliferation, differentiation and apoptosis in cancer. This makes sphingolipids 
considerable targets for cancer treatment and development new chemotherapeutic 
agents. Ceramide is the crucial molecule for sphingolipid metabolism. The disruption of 
the balance between ceramides and other molecules may result in drug resistance and/or 
cell proliferation and growth.  
Ceramide activates many apoptotic molecules in cancer cells. Cathepsin D is 
one of these molecules and involved in induction of apoptosis. Stefanis et al. 
demonstrated that increasing of ceramide levels in HT-29 colon cancer cells induce 
apoptosis via activating of Cathepsin D (De Stefanis, et al., 2002). Ceramides are 
syhtesized in ER and transported to golgi apparatus via CERT protein and processed to 
SM or GlcCer. Swanton et al. showed that while CERT was downregulated in HCT-116 
(HCT) colon carcinoma, MDA-MB-231 (MDA) breast adenocarcinoma, and A549 non-
small-cell lung carcinoma cells sensitized to paclitaxel (Swanton, et al., 2007). 
Pchejetski et al. demonstrated that downregulation of SK-1 enzyme sensitized to 
docetaxel in prostate adenocarcinoma cells and mouse models (Pchejetski, et al., 2005). 
 
1.5. The Aims of The Study 
 
Ceramides are second messengers in the cell. Normally, they are found in lipid 
bilayer. Beside the structural roles in the cell, they are also involved in cellular 
processes such as apoptosis, differentiation and growth. Increases in ceramide levels 
leads to cell death in cancer cells.  But, on the other hand apoptotic ceramides converts 
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into antiapoptotic sphingosine-1-phosphate via phosphorylation of sphingosines by 
Sphingosine kinase-1 enzyme. Furthermore, apoptotic ceramides glucosylated to 
antiapoptotic molecule glucosylceramides by glucosylceramide synthase. Inhibition of 
GCS by PDMP and inhibition of SK-1 by SK-1 inhibitor may block formation of 
GlcCer and S1P,  also synthesis of ceramides are induced by CerS families. Thus, this 
pathway may be a good target in chemotherapy (Figure 1.12). Resveratrol is naturally 
occurring antioxidant in plants and have many important properties such as inhibition of 
tumor initiation, promotion and progression. It is known that resveratrol induced 
apoptosis in cancer cells. But still, many unknowns exist in resveratrol induced cell 
death. Taken together, there may be a link between resveratrol and ceramide induced 
apoptosis in AML cells. The aim of this project is to examine cytotoxic and apoptotic 
effects of resveratrol, ceramide analogs and inhibitors of SK-1 and GCS on HL60 cells 
and determine possible synergistic, cytotoxic, and apoptotic effects. Then, evaluating 
upregulation or downregulation CerS family genes, GCS and SK-1 gene members in 
reponse to resveratrol in HL60 cells. 
 
 
Figure  1.12. Balance Between Ceramide/S1P and Ceramide/GlcCer 
(Source: Adapted from Saddoughi, 2008)
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CHAPTER 2                                                                    
MATERIAL AND METHODS 
2.1. Chemicals 
 
Resveratrol, bovine serum albumin serum, trypan blue solution, β-
mercaptoethanol, dimethyl sulfoxide (DMSO), agarose, coomassie blue were obtained 
from Sigma, USA. 10 mM stock solution of resveratrol was prepared with DMSO and 
stored at -20ºC. C8:ceramide, N-(2-hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl)-
decanamide, hydrochloride (PDMP), and SK-1 inhibitor were obtained from Cayman 
Chemicals (USA),  dissolved in DMSO, and stored at -20ºC. The final concentration of 
DMSO did not exceed more than 0.1% in culture.  Heat-inactivated fetal bovine serum 
(FBS), L-glutamine, penicillin-streptomycin were obtained from Biological Industries, 
Israel. RNA isolation kit was obtained from Macherey Nagel, Germany. Taq DNA 
Polymerase was obtained from Finnzymes, Finland. dNTP set, DNA ladder, reverse 
transcriptase reaction kit was obtained from Fermentas, Canada. Caspase-3 colorometric 
assay kit was obtained from BioVision, USA. JC-1 mitochondrial membrane potential 
detection kit was obtained from APO LOGICTM JC-1 from BACHEM, USA.  
 
2.2. Cell Lines and Culture Conditions 
 
Human HL60 APL cells were kindly provided by Dr. Ali Ugur Ural from 
Gulhane Military Medical School, Department of Hematology.  They were grown and 
maintained in RPMI1640 medium containing 10% fetal bovine serum, and 1% 
penicillin-streptomycin at 37°C in 5% CO2 incubator. Medium was refreshed every 3 
days. The cells were collected from 75cm
2
 flask to 50ml falcons and were centrifugated 
at 800g 10 minutes at room temperature. After centrifugation, supernatant was removed 
and pellet was resuspended in 4 ml PBS and repeated centrifugation process at 800g 10 
minutes. Then, supernatant was removed and pellet was resuspended with 20ml 
RPMI1640 (%10 FBS, %1 Penicillin-Streptomycin), transferred to 75cm
2 
filtered flask 
and incubated in CO2 incubator. 
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2.3. Measurement of Cell Growth by XTT Cell Proliferation Assay 
 
XTT cell proliferation assay is based on the reduction of XTT dye into formazan 
compound which is measurable via spectrophotometer by active mitochondrial enzyme 
dehydrogenases.  
The IC50 values (drug concentration that inhibits cell growth 50% as compared 
to control) of resveratrol; a ceramide analogue, C8:ceramide; GCS enzyme inhibitor 
(PDMP) and IC10 value of SK-1 enzyme inhibitor were determined from cell 
proliferation plots obtained by XTT assay as described before.(Gucluler and Baran, 
2009). 2x10
4
 HL60 cells were seeded into 96-well plates containing 200 μl growth 
medium in the absence or presence of increasing concentrations of resveratrol, 
C8:ceramide, PDMP or SK-1 inhibitor. After 72 hr incubation in %5 CO2 , they were 
treated with 40 μl of XTT reagent for 4 hours. Then, the absorbances of the samples 
were measured under 490 nm wavelength of light by Elisa reader (Thermo Electron 
Corporation Multiscan Spectrum, Finland) and graphed cell proliferation plots. Finally, 
IC50 values of resveratrol, C8:ceramide or PDMP and IC10 values of SK-1 inhibitor 
were calculated from cell proliferation plots. In order to determine possible synergistic 
effects of resveratrol in combination with these ceramide metabolism manipulating 
chemicals, increasing concentrations of resveratrol were applied together with IC50 
value of C8:ceramide or PDMP or IC10 value of SK-1 inhibitor. The same procedure of 
XTT cell proliferation assay was applied for these set of experiments as mentioned 
above.  
 
2.4. Isobologram Analysis of Median Dose Effects 
 
It was used the CalcuSyn for Windows computer program (CalcuSyn software, Biosoft, 
Cambridge, UK) for isobologram analysis (Zhao, et al., 2010). Isobologram analysis 
was conducted using the computer software and analyzed resveratrol with SK-1 
inhibitor, C8:ceramide and PDMP. Experimental data points, represented by dots 
located below, on, or above the line, indicate synergism, additivity, and antagonism, 
respectively. The CI is an analysis of the combined effects of 2 drugs, using a median 
effect plot analysis. A CI value <1 indicates a synergistic effect (0.1-0.5 strong 
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synergism; <0.1 very strong synergism); a CI value of 1 indicates additive effect; and a 
CI value >1 an antagonistic effect (3.3-10 strong antagonism, >10 very strong 
antagonism). 
 
2.5. Measurements of Caspase-3 Enzyme Activity 
 
Changes in caspase-3 enzyme activities were determined using caspase-3 
colorimetric assay kit (R&D Systems, USA) as described before (Baran, et al., 2007). 
1x10
6
 cells were seeded in 6-well plate in 2 ml growth medium in the absence or 
presence of increasing concentrations of resveratrol, C8:ceramide, PDMP or SK-1 
inhibitor or combination of resveratrol with others. After 72 hr incubation in %5 CO2, 
the cells were collected by centrifugation at 1000g for 10 minutes. The pellets were 
treated with 100 µl of cold lysis buffer (1X) in order to obtain cell lysate. Then, the cell 
lysates were incubated on ice for 10 minutes and they were centrifuged at 14000g for 1 
minute. Following the centrifugation, supernatants were transferred to new eppendorf 
tubes. In order to measure caspase-3 enzyme activity, reaction mixture include 50 µl of 
reaction buffer (2X), 50 µl of the samples and 5 µl of caspase-3 colorimetric substrate 
was added into 96-well plate and incubated for 2 hours at 37˚C in 5% CO2 incubator. 
Absorbances of the samples were read under 405 nm wavelength of light via the ELISA 
reader (Thermo Electron Corporation Multiskan Spectrum, Finland). Then, protein 
concentrations were measured by Bradford assay. Finally, enzyme activity levels were 
normalized to protein concentrations that was determined by Bradford assay. In 
Bradford protein assay, it is used coomassie blue dye which converted into bluer form 
of dye while binding to proteins. Absorbance was read under 595nm via ELISA reader 
(Thermo Electron Corporation Multiskan Spectrum, Finland) and while protein 
concentration was increased, the absorbance was also increased and according to BSA 
protein concentrations, the concentration of proteins were calculated.  
 
2.6. Detection of the Loss of Mitochondrial Membrane Potential 
(MMP) 
 
The loss of mitochondrial membrane potential was detected by JC-1 
mitochondrial membrane potential (MMP) kit (Cell Technology, USA). 1x10
6
 HL60 
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cells were seeded in 6-well plate in 2 ml growth medium and treated with different 
concentrations of resveratrol, C8Ceramide, SK-1 inhibitor or PDMP alone or 
combination of resveratrol with the others, incubated for 72 hours and after that time, 
HL60 cells treated with resveratrol, C8:ceramide, SK-1 inhibitor or PDMP alone or 
combination of resveratrol with the others were collected by centrifugation at 1000g for 
10 minutes. Supernatants were removed and the pellets were dissolved in 500 µl of JC-1 
dye before their incubation at 37˚C in 5% CO2 for 15 minutes. Then, the mixtures were 
centrifuged at 1000g for 5 minutes. Pellets were resuspended in 2 ml of blank media in 
order to remove excess dye and they were centrifuged at 1000g for 5 minutes. All 
pellets were resuspended with 500 µl of blank media and 150 µl from each was added 
into black 96-well plate. The aggregate red form of the dye which is found in inner 
mitochondria has absorption/emission maxima of 585/590 nm and the monomeric green 
form of the dye which was released to the cytoplasm due to the loss of the MMP has 
absorption/emission maxima of 510/527 nm. The plate was read at these wavelengths 
by fluorescence Elisa reader (Thermo Varioskan Spectrum, Finland). Finally, green/red 
(510/585) values were calculated to determine the changes in MMP.  
 
2.7. Total RNA Isolation and RT-PCR 
 
The expression levels of ceramide metabolizing genes were determined by 
reverse transcriptase-polymerase chain reaction (RT-PCR). 3x10
6
 cells were seeded in 
6-well plate in 2 ml growth medium and treated with different concentrations of 
resveratrol for 72 hours in 5% CO2. Total RNA was extracted using a Nucleospin Total 
RNA isolation kit (Machery-Nagel, USA) as described by the manufacturer. The 
amount and quality of RNA were measured by Nanodrop Photospectrometer 
(NanoDrop 1000 THERMO, USA). 5 μg of total RNA was reverse transcribed into 
cDNA by reverse transcriptase enzyme (Fermentas, USA). After incubation at 42 °C for 
50 min, the reactions were stopped at 95 °C for 5 min.The resulting total cDNA was 
then used to determine expression levels of CerS1, CerS2, CerS 4, CerS5, CerS6, SK-1, 
and GCS. Expression levels of β-actin were used as internal positive control. The primer 
sequences were as follows; 
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Table  2.1. Forward and Reverse Sequence of Primers 
CerS1 Forward (5’CTATACATGGACACCTGGCGCAA3’) 
CerS1 Reverse (5’TCAGAAGCGCTTGTCCTTCACCA3’) 
CerS2 Forward (5’ GCTGGAGATTCACAT3’)    
CerS2 Reverse (5'GAAGACGATGAAGAT3’) 
CerS4 Forward (5’TGCTGTCCAGTTTCAACGAG3’) 
CerS4 Reverse (5’GAGGAAGTGTTTCTCCAGCG3’) 
CerS6 Forward (5’-CTCCCGCACAATGTCACCTG-3’) 
CerS6 Reverse (5’-TGGCTTCTCCTGATTGCGTC-3’) 
SK-1 Forward (5’CCGACGAGGACTTTGTGCTAAT3’) 
SK-1 Reverse (5’GCCTGTCCCCCCAAAGCATAAC3’) 
GCS Forward (5’ATGACAGAAAAAGTA3’) 
GCS Reverse (5’GGACACCCCTGAGTG3’) 
β-Actin Forward (5’CAGAGCAAGAGAGGCATCCT3’) 
β-Actin Reverse (5’TTGAAGGTCTCAAACATGAT3’) 
 
Products of PCR reactions were visualized under UV after running them on 2% 
agarose gel electrophoresis including ethidium bromide at 90 V for 1h.  
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Table  2.2. The Ingredient of Reverse Transcription Reaction 
Ingredients Amount 
RNAse Free Water 5 μL  
  Total RNA (5 μg) 5 μl 
10X Buffer   
 
2 μl 
Random Primers (0.5 μg/L)  0.7 μL  
RNAse Inhibitor (50U/μL)  0,7 μL  
MgCl2 (25 mM)  4 μL  
dNTP (10 mM)  2 μL  
Moloney Murine Reverse 
Transcriptase Enzyme (200 
U/μL)  
0,7 μL  
Total  20 μL  
 
Table  2.3. Ingredients of PCR Solutions for SK-1 and GCS 
SK-1, GCS 
Reaction Mixture Amount (µL) 
PCR grade water 32.3 
Reaction buffer (10x) 5 
MgCl2 (25 mM) 5 
dNTP (10 mM) 4 
Primer forward (25 pmol/μL) 0.5 
Primer reverse (25 pmol/μL) 0.5 
cDNA  2 
Taq DNA Polymerase 0.3 
Total Mixture 50 
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Table  2.4. Ingredients of PCR Solutions for CerS1 
CerS1 
Reaction Mixture Amount (µL) 
PCR grade water 31.3 
Reaction buffer (10x) 5 
MgCl2 (25 mM) 5 
dNTP (10 mM) 4 
Primer forward (25 pmol/μL) 1 
Primer reverse (25 pmol/μL) 1 
cDNA  2 
Taq DNA Polymerase 0.7 
Total Mixture 50 
 
Table  2.5. Ingredients of PCR Solutions for CerS2, CerS5 and CerS6 
CerS2, CerS5, CerS6 
Reaction Mixture Amount (µL) 
PCR grade water 32.3 
Reaction buffer (10x) 5 
MgCl2 (25 mM) 5 
dNTP (10 mM) 4 
Primer forward (25 pmol/μL) 0.5 
Primer reverse (25 pmol/μL) 0.5 
cDNA  2 
Taq DNA Polymerase 0.7 
Total Mixture 50 
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Table  2.6. Ingredients of PCR Solutions for CerS4 
CerS4 
Reaction Mixture Amount (µL) 
PCR grade water 31.8 
Reaction buffer (10x) 5 
MgCl2 (25 mM) 4.5 
dNTP (10 mM) 4 
Primer forward (25pmol/μL) 0.5 
Primer reverse (25 pmol/μL) 0.5 
cDNA  2 
Taq DNA Polymerase 0.7 
Total Mixture 50 
 
Table  2.7. Ingredients of PCR Solutions for β-actin 
β-actin 
Reaction Mixture Amount (µL) 
PCR grade water 30.8 
Reaction buffer (10x) 5 
MgCl2 (25 mM) 5 
dNTP (10 mM) 4 
Primer forward (25 pmol/μL) 1 
Primer reverse (25 pmol/μL) 1 
cDNA  2.5 
Taq DNA Polymerase 0.7 
Total Mixture 50 
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CHAPTER 3                                                                                  
RESULTS AND DISCUSSION 
3.1. Cytotoxicity Analysis in HL60 Cells  
 
3.1.1. Cytotoxic Effects Of Resveratrol, C8:Ceramide, Sk-1 Inhibitor 
and PDMP on HL60 Cells  
 
There were dose dependent cytotoxic effects of resveratrol, C8:Ceramide, 
PDMP, and SK-1 inhibitor on HL60 cells as measured by XTT assay. The cells treated 
with increasing concentration of resveratrol which were 1, 5, 10, 20, 50 and 100 µM 
resveratrol and it was calculated 3, 5, 15, 29, 45 and 55% decreases in cell proliferation 
of HL60 cells, respectively (Figure 3.1).  IC50 values of resveratrol was calculated from 
cell proliferation plots and found to be 75 µM (Figure 3.1). 
 
 
Figure  3.1. Antiproliferative effects of Resveratrol on HL60 cells 
 
HL60 cells were treated with increasing concentrations of exogenous C:8 
Ceramide and conducted XTT cell proliferation assay. HL60 cells treated with 1, 10, 20, 
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50 µM C:8 Ceramide and it was calculated 4, 11, 20, 57 % decrases in cell proliferation, 
respectively (Figure 3.2.). IC50 value of C8:ceramide is 45 µM (Figure 3.2). 
 
 
Figure  3.2. Antiproliferative Effects of Ceramide on HL60 cells 
 
Glucosylceramide synthase inhibitor, PDMP, was exposed to HL60 cells with 
the increasing concentration of 1, 10, 20, 50 µM PDMP and assessed cell proliferation. 
Then cell proliferation plots were established and it was calculated 0, 9, 21, 41 % 
decreases in cell proliferation. IC50 value of PDMP was found to be as a 61 µM (Figure 
3.3). 
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Figure  3.3. Antiproliferative Effects of PDMP on HL60 cells 
 
HL60 cells were exposed to Sphingosine kinase-1 inhibitor in order to assess 
cytotoxic effects. There were 0, 27, 63, 62, 76 % decreases in response to increasing 
concentration of 1, 10, 15, 20, 50 µM SK-1 inhibitor (Figure 3.4). IC10 value 
(Inhibitory concentration of 10%) was calculated according to cell proliferation plots 
and it was found as 5 µM (Figure 3.4).  
 
 
Figure  3.4. Antiproliferative Effects of SK-1 inhibitor on HL60 cells 
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3.1.2. Resveratrol in Combination with C8:Ceramide, PDMP or SK-1 
Inhibitor Showed Significant Synergistic Cytotoxic Effects  on 
HL60 Cells  
 
The possible synergistic antiproliferative effects of combination of resveratrol 
with the ceramide analogue and inhibitor of ceramide metabolizing enzymes were 
assessed by XTT cell proliferation assay. Resveratrol combined with C8:ceramide, 
PDMP and SK-1 inhibitor and determined cytotoxic effects. HL60 cells exposed to 
IC50 value of 45 µM C8:ceramide, which induces de novo generation of  ceramides and 
after 4 hours, increasing concentrations of 1, 2, 5, 10, 20, 50 µM resveratrol were added 
onto HL60 cells and examined decreases in cell proliferation 75, 76, 80, 81, and 82%, 
respectively, as compared to untreated controls (Figure 3.5). Combination of the same 
concentration of resveratrol with IC50 value of 61 µM PDMP which provides 
accumulation of ceramides, resulted in 66, 71, 76, 88, and 89% decreases in 
proliferation of HL60 cells, respectively (Figure 3.6). The combination of IC50 value of 
SK-1 inhibitor and resveratrol did not show any synergistic effect. So it was used IC10 
value of SK-1 inhibitor. IC10 value of 5 µM SK-1 inhibitor, in combination with 1, 2, 5, 
10, 20, 50 µM resveratrol caused  19, 28, 39, 44, and 71% decreases in cell 
proliferation, respectively, as compared to untreated controls (Figure 3.7). 
 
 
Figure  3.5. Effects of Resveratrol/C8:ceramide combinations on proliferation of HL60 
cells 
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Figure  3.6. Effects of Resveratrol /PDMP combinations on proliferation of HL60 cells 
 
 
Figure  3.7. Effects of Resveratrol/SK-1 inhibitor combinations on proliferation of HL60        
cells 
 
According to isobologram analysis via using CalcuSyn software, synergistic 
effects of resveratrol in combination with C:8 Ceramide, PDMP and SK-1 inhibitor 
were determined and calculated CI values which means median doses (Figure 3.8). The 
CI values of resveratrol in combination with C8:Ceramide, PDMP and SK-1 inhibitor 
were 0,079615, 0.00716 and 0.74606, respectively, in HL60 cells. CI value which is 
below than 1 indicates a synergistic effect (0.1-0.5 strong synergism; <0.1 very strong 
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synergism). The results demonstrated that combination of resveratrol with C:8 
Ceramide and PDMP indicated very strong synergism, however combination of 
resveratrol with SK-1 inhibitor indicated synergism in HL 60 acute myeloid leukemia 
cells. Because, in this combination, it was used IC10 value of SK-1 inhibitor. 
 
  
  
  
 
Figure  3.8. Isobologram analysis of resveratrol/C:8 Ceramide, /PDMP and /SK-1    
inhibitor on HL60 cells 
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3.2.  Evaluation of Apoptosis in HL60 Cells 
 
3.2.1. Changes in Caspase-3 Enzyme Activity Showed Higher 
Apoptotic Effects of Resveratrol with C:8 Ceramide, PDMP or 
SK-1 Inhibitor as Compared to Any Agent Alone 
 
Caspase-3 enzyme is in the center of apoptotic pathway and the activation of this 
enzyme can be considered as an indicator of apoptosis. Caspase-3 enzyme activity was 
measured in HL60 cells exposed to any agent alone or combinations of 
resveratrol/C8:Ceramide, resveratrol/PDMP and resveratrol/SK-1 inhibitor. HL60 cells 
treated with 5 and 10 µM resveratrol showed 1.11, and 1.14-fold increases in caspase-3 
enzyme activity as compared to untreated controls while 45 µM C8:ceramide, 61 µM 
PDMP, and 5 µM SK-1 inhibitor resulted in 2.17, 1.81, and 1.71-fold increases in 
caspase-3 enzyme activity (Fig. 3.9). On the other hand, 5 µM Resveratrol in 
combination with the same concentrations of C8:Ceramide, PDMP, or SK-1 inhibitor 
resulted in 2.96, 2.62, and 2.45-fold increases in the enzyme activity, respectively (Fig. 
3.9). There were 3.77, 2.68, and 2.4-fold increases in caspase-3 enzyme activity in 
HL60 cells incubated with combination of the same concentrations of C8: Ceramide, 
PDMP, SK-1 inhibitor and 10 µM resveratrol, respectively (Figure 3.9). 
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Figure  3.9. Fold changes in caspase-3 enzyme activity in response to resveratrol, C:8 
Ceramide, PDMP, SK-1 inhibitor alone and combination of resveratrol, 
with C8:Ceramide, PDMP and SK-1 inhibitor  
 
3.2.2. Effects of Resveratrol Alone and in Combination with 
C8:Ceramide, PDMP, or SK-1 Inhibitor on Mitochondrial 
Membrane Potential  
 
Caspase-3 enzyme activity was significantly increased in HL60 cells in response 
to combination or alone resveratrol, PDMP, SK-1 and C8:Ceramide. In order to confirm 
caspase-3 enzyme activity results, it was conducted the same set of experiment to 
examine the changes in mitochondrial membrane potential. Moreover, mitochondrial 
membrane potential also changes while apoptosis induced in the cell. The results 
revealed that there were 1.37 and 1.45-fold increases in cytoplasmic/mitochondrial JC-1 
in response to 5 and 10 µM resveratrol, respectively (Fig. 3.10). HL60 cells treated with 
45 µM C8:Ceramide or 61 µM PDMP or 5 µM SK-1 inhibitor or showed 25.98, 1.18 or 
10.29-fold increases in cytoplasmic/mitochondrial JC-1. We applied combination of 5 
and 10 µM resveratrol together with the same doses C8:Ceramide or PDMP or SK-1 
inhibitor and observed 32.67 and 79.50-fold or 12.87 and 14.28-fold or 1.75 and 2.41-
fold increases in cytoplasmic/mitochondrial JC-1, respectively, as compared to 
untreated controls (Fig. 3.10).  
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Figure  3.10. Fold changes in cytoplasmic/mitochondrial JC-1 in HL60 cells exposed to  
alone or combinations of resveratrol with C8:Ceramide, PDMP, or SK-1 
inhibitor 
 
3.3. Gene Expression Analysis in HL60 Cells 
 
3.3.1. Resveratrol Induces de novo Ceramide Generation and 
Ceramide Accumulation by Increasing Expression Levels of 
CerS Genes and Decreasing Expression Levels GCS and SK-1 
Genes  
 
Expression levels of ceramide metabolizing genes in HL60 cells treated with 
increasing concentrations of resveratrol (1, 10, 20, and 50 µM) were determined by RT-
PCR. The results revealed that there were significant increases in expression levels of 
CerS1, CerS2, CerS4, CerS5, and CerS6 genes and decreases in expression levels of 
GCS and SK-1 in a dose-dependent manner (Fig. 3.11). We quantified expression levels 
of the genes and detected 1.5, 1.98, 1.79, 1.27 and 1.96-fold increases in expression 
levels of CerS1, CerS2, CerS4, CerS5, and CerS6 and 0.5 and 0.6-fold decreases in 
expression levels of GCS and SK-1 genes, respectively, as normalized to Beta Actin 
levels and compared to untreated control (Table 3.1). 
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Figure  3.11. mRNA levels of ceramide-metabolizing genes and ceramide synthase genes 
in response to resveratrol in HL60 cells 
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Table  3.1. Quantification of gene expression levels in reponse to 50µM resveratrol 
treatment 
Gene Control 50µM Resveratrol 
CerS1 100 150 
CerS2 100 198 
CerS4 100 179 
CerS5 100 127 
CerS6 100 196 
SK-1 100 50 
GCS 100 40 
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CHAPTER 4                                                               
CONCLUSION 
There are different strategies for the treatment of acute myeloid leukemia. But, 
significant problems are observed in patients during treatment with these chemicals. 
Thus, natural products that may have strong anticancer potential always attract the 
attention of clinicians and basic science researchers. In this study, it was demonstrated 
anticancer potentials of resveratrol on human acute myeloid leukemia cells in addition 
to identifying a novel mechanism of resveratrol-induced apoptosis that involves 
bioactive sphingolipids. On the other hand, it has increased antiproliferative and 
apoptotic effects of resveratrol on HL60 cells by targeting ceramide-generating and 
ceramide clearance genes toward generation and/or accumulation of apoptotic 
ceramides. It was observed that resveratrol, C8:Ceramide which induce de novo 
generation of apoptotic ceramides, PDMP, which inhibits GCS enzyme, and SK-1 
inhibitor showed cytotoxic effects of HL60 cells in a dose-dependent manner. 
Resveratrol application resulted in increases in caspase-3 enzyme activity and loss of 
mitochondrial membrane potential. Since the mitochondrial membrane potential and 
caspases are downstream targets of ceramides, treatment of HL60 cells with 
C8:ceramide, PDMP, or SK-1 inhibitor also resulted in increases in caspase-3 enzyme 
activity and loss of  mitochondrial membrane potential. As we manipulate the cells to 
increase intracellular generation or accumulation of ceramides by biochemical 
approaches, we observed significant synergistic cytotoxic effects of resveratrol on HL60 
cells. Combinations of resveratrol with C8:ceramide, PDMP, or SK-1 inhibitor resulted 
in more apoptotic cells as compared to any agent alone. These findings were in 
agreement with the literature (Bielawska, et al., 2008,  Szulc, et al., 2006 and Baran, et 
al., 2007). It was shown that application of ceramide analogs or their mimetics induces 
apoptosis and/or growth arrest in various types of cancer cells (Bielawska, et al., 2008 
and Szulc, et al., 2006). It was clearly shown that there was significant inhibition of 
tumor growth and progression in response to ceramidoids, a synthetic ceramide, in head 
and neck squamous cancer cells and some other cancer models, in vivo (Bielawska, et 
al., 2008 and Senkal, et al., 2006). Different structural analogs of ceramides have also 
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been shown to induce apoptosis in breast cancer cells (Struckhoff, et al., 2004) and drug 
resistant MCF-7/Adr cells (Crawford, et al., 2003). It was shown that increasing 
expression levels of ceramide synthase gene (CerS1) in imatinib-resistant and  sensitive 
K562 cells triggered apoptosis and increased sensitivity of these cells to imatinib 
(Baran, et al., 2007). Targeting ceramide clearance enzymes is another important 
strategy to increase intracellular concentrations of ceramides (Ogretmen, 2006). 
Inhibition of SK-1 enzyme to block conversion of apoptotic ceramide to antiapoptotic 
S1P is a novel treatment modality for the treatment of cancers. It was shown in living 
animal models that inhibition of SK-1 blocked cell growth and proliferation and 
induced apoptosis (French, et al., 2006). Inhibition of S1P receptors or application of 
monoclonal antibodies against S1P have also been shown to be effective protocols for 
the treatment of cancers (Visentin, et al., 2006). Baran et al. showed that partial 
inhibition of SK-1 by siRNA resulted in apoptosis in imatinib-resistant K562 chronic 
myeloid leukemia cells (Baran, et al., 2007). Glucosylceramide synthase enzyme has 
been shown to be involved in drug resistance in cancer. Thus, inhibition of GCS is also 
a novel treatment option for cancer cells. Adriamycin-resistant MCF-7 cells showed 
sensitivity and underwent apoptosis in response to GCS inhibitors, while overexpression 
of GCS in MCF-7 cells resulted in multidrug resistance to several agents (Liu, et al., 
1999 and Yuan, et al., 1997). Moreover, combination of GCS inhibitor with some 
anticancer agents, such as doxorubicin, tamoxifen, vincristine, and taxol, induced 
apoptosis synergistically in various human cancer cells (Morjani, et al., 2001), 
(Senchenkov, et al., 2001). Interestingly, our RT-PCR results showed that there were 
significant increases in the expression levels of CerS1, CerS2, CerS4, CerS5, and CerS6 
genes in response to resveratrol in a dose-dependent manner in HL60 cells. In parallel 
studies, we have also detected significant decreases in expression levels of SK-1 and 
GCS in a dose-dependent manner in HL60 cells. Increased expression of CerS genes in 
response to chemotherapeutic stress has also been shown in different cancer cells. There 
was increased ceramide synthase enzyme activity in response to daunarubicine and 
etoposide (Bose and Kolesnick, 2000 and Perry, 2000). A camptohotecine derivative 
CPT-11 and hexadevylephosphocholine agents also induced apoptosis by upregulating 
ceramide synthase genes (Wieder, et al., 1998). The results of this study showed for the 
first time that resveratrol induces apoptosis through both increasing de novo generation 
of apoptotic ceramides and decreasing conversion of apoptotic ceramides to 
antiapoptotic S1P and GluCer. On the other, our data strongly suggest that targeting 
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ceramide metabolism increased chemosentivity of acute myeloid leukemia cells to 
resveratrol. Since ceramides are the regulators of vitally important biological processes, 
targeting ceramide metabolizing genes and their end products may be an open a new 
way of the treatment of different types of cancers. 
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